Skip to main content
Shenzhen Chipscreen Biosciences Co., Ltd. logo

Shenzhen Chipscreen Biosciences Co., Ltd. — Investor Relations & Filings

Ticker · 688321 ISIN · CNE100003LW0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 967 across all filing types
Latest filing 2025-04-25 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688321

About Shenzhen Chipscreen Biosciences Co., Ltd.

https://www.chipscreen.com/en/

Shenzhen Chipscreen Biosciences Co., Ltd. specializes in the discovery and development of original small molecule innovative drugs. The company leverages its proprietary chemical genomics-based drug discovery and early evaluation platform to address unmet medical needs in oncology, metabolic diseases, and autoimmune disorders. Its portfolio includes Chidamide (Epidaza), a selective histone deacetylase (HDAC) inhibitor approved for peripheral T-cell lymphoma and advanced breast cancer, and Chiglitazar (Bilessyl), a novel PPAR pan-agonist for type 2 diabetes. Chipscreen Biosciences maintains an integrated R&D system covering drug discovery, clinical development, and commercialization, focusing on molecular mechanisms and translational medicine to provide novel therapeutic solutions.

Recent filings

Filing Released Lang Actions
关于购买董监高责任险的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shenzhen Microchip Biotechnology Co., Ltd. regarding the purchase of directors and officers liability insurance (董监高责任险). It details the insurance plan, including insured parties, coverage limits, premiums, and authorization for management to handle related matters. The document mentions board and supervisory meetings and the submission of the proposal to the 2024 annual general meeting for approval. The content is a formal announcement about a corporate governance and risk management measure, not a financial report, earnings release, or regulatory filing. It does not contain financial statements or detailed financial data. The document is not a report itself but an announcement of a corporate action related to governance and risk management. Therefore, the most appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement that does not fit other specific categories.
2025-04-25 Chinese
关于提请股东大会授权董事会以简易程序向特定对象发行股票的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shenzhen Microchip Biotechnology Co., Ltd. regarding a proposal to the shareholders' meeting to authorize the board to issue shares to specific investors via a simplified procedure. It details the authorization scope, issuance conditions, pricing, use of proceeds, and related procedural matters. The document is a formal announcement about a capital raising plan requiring shareholder approval, not the actual issuance or financial report. It does not contain financial statements or results but is a regulatory announcement about a capital/financing update. The document length is 3188 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the document fits best under Capital/Financing Update (CAP).
2025-04-25 Chinese
关于召开2024年度股东大会的通知
AGM Information Classification · 100% confidence The document is a detailed notice about the convening of the 2024 Annual General Meeting (AGM) of Shenzhen Microchip Biotechnology Co., Ltd. It includes the date, voting methods, agenda items for shareholder approval, instructions for attendance and voting, and an authorization proxy form. The content focuses on the organization and procedural details of the AGM rather than presenting financial results or reports themselves. The document length is about 4556 characters, which is consistent with a meeting notice rather than a full report. There is no financial data or management discussion included, only the announcement and procedural information for the AGM. Therefore, this document fits the category of AGM Information (AGM-R).
2025-04-25 Chinese
深圳微芯生物科技股份有限公司2024年度向特定对象发行A股股票的论证分析报告（修订稿）
Capital/Financing Update Classification · 100% confidence The document is a detailed report titled "2024 年度向特定对象发行A 股股票的论证分析报告 (修订稿)" which translates to "2024 Annual Report on the Issuance of A Shares to Specific Objects (Revised Draft)". It discusses the company's plan to issue A shares to specific investors, including the background, necessity, pricing, legal compliance, and impact on shareholders. The content includes detailed financial assumptions, regulatory references, issuance procedures, and commitments from controlling shareholders. This is a comprehensive document related to a capital raising event through a private placement of shares. It is not a simple announcement or a brief summary but a full analytical report supporting the issuance. Therefore, it fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document length (15,000 characters) and detailed content confirm it is not a mere announcement or regulatory filing but a substantive financing report.
2025-04-25 Chinese
深圳微芯生物科技股份有限公司2024年度向特定对象发行A股股票募集资金使用的可行性分析报告（修订稿）
Capital/Financing Update Classification · 95% confidence The document is titled as a "2024年度向特定对象发行A股股票募集资金使用的可行性分析报告（修订稿）" which translates to "2024 Feasibility Analysis Report on the Use of Funds Raised by Private Placement of A Shares (Revised)". It details the company's plan to raise capital through a specific issuance of shares to certain investors, including the amount to be raised, the intended use of the funds (innovation drug R&D, manufacturing base, and working capital), and the necessity and feasibility of these investments. The document discusses the capital raising plan, the use of proceeds, and the impact on the company's financial and operational status. It is not a full financial report, earnings release, or regulatory filing but a detailed capital/financing update related to a fundraising activity. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length (over 10,000 characters) and detailed content confirm it is the actual report, not just an announcement or certification.
2025-04-25 Chinese
关于最近五年未被证券监管部门和证券交易所采取监管措施或处罚的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement from Shenzhen Microchip Biotechnology Co., Ltd. stating that in the past five years, the company has not been subject to any regulatory measures or penalties by securities regulatory authorities or stock exchanges. It references a board meeting and a self-inspection result but does not contain financial statements or detailed financial data. The document is brief (569 characters) and serves as a regulatory compliance disclosure rather than a full report or detailed filing. It does not fit into categories like Annual Report, Interim Report, or Audit Report. It is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-04-25 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.